Capricor Therapeutics Profit Margin

The latest profit margin for CAPR is -Infinity% as of March 2026. That compares with -5.53% in the prior-year period — down Infinity% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Capricor Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, CAPR's profit margin moved from -5.53% to -Infinity% — a Infinity% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Capricor Therapeutics's valuation or profitability profile.

Against Healthcare companies, CAPR currently prints -Infinity% for profit margin, while the sector average sits near 15.58%. That is roughly Infinity% below the sector mean. Large gaps often invite a closer look at Capricor Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Capricor Therapeutics converts resources into returns. At -Infinity%, CAPR may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -5.53% in the prior-year period — down Infinity% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CAPR's profit margin (-Infinity%), review year-over-year change from -5.53%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.